Via Scoop.it – inPharmatics
In other words, computing in the banking industry is perfected, so why can’t healthcare get its act together? (Irrespective of the sea change of difference between simple financial data and incredibly complex medical data.) …
Via hcrenewal.blogspot.com
Via Scoop.it – inPharmatics
Do you want your boss to realize the full potential of social media? Yesterday on Pixels & Pills we talked about John Mack’s observation that very few senior executives attend digital pharma conferences.
Via http://www.pixelsandpills.com
(HealthDay News) -- While smoking has long been linked to cancer, its frequent companion, drinking, may be as well, a new study suggests.
Three new studies presented at a medical meeting this week find a link between heavy boozing and a rise in risk for the number one cancer killer.
On the other hand, studies also suggest that heavier people are less likely to develop lung cancer than smaller folk, and black tea might help ward of the disease, as well.
The findings were to be presented at the annual meeting of the American College of Chest Physicians, Oct. 22-26, in Honolulu.
More Americans die from lung cancer than any other form, according to the U.S. Centers for Disease Control and Prevention (CDC). In 2007, the most recent year for which statistics are available, more than 203,000 people in the United States were diagnosed with lung cancer, and nearly 159,000 died. Read more...
08-02-2012 23:17 NicholasAnderson.info Nicholas Anderson, Author of "NOC British Secret Operations" interviewed by Joseph Dowdy. stem cell transplantation... can't say diseases to get hopes up. oversaw exfiltration of doctor who is an expert at stem cell transplantation. not an expert or doctor, but can speak from experience. much of this may bother others. there is an assumption one belief is correct and others are wrong. stem cells are human and animal organisms derived from embryos. they can renew themselves in others bodys/cells/tissues. they are not factory assembled. they are coming from aborted tissue that would be thrown away. in the soviet union, they experimented on them. again, author does not know all about stem cells. speak to your doctor and do your own research. for most basic info on the doctor from the soviet union, see the book. was this post cold war debriefing? was he a scientist who knew a lot? no. he defected in mid-70s. the west/us/uk milked him for info. they did nothing with that info. he returned to the new russia after the collapse and started again. what has he been doing since? is the russian medicine better?? yes, it's more advanced or the west has simply got their advancements from russia. this is like a replacement battery for tissue/cells/body; it must be recharged. it does offer terminally ill chance to live longer; not a medical diagnosis. if people know enough about stem cells, they probably know what it is... it's good for regenerating tissue without ...
Read this article:
Insights Into MI6: Stem Cell Transplantation - Video
09-02-2012 22:12 Stem Cell Therapy latest news - Jan 2012, MS options Contact Kevin for help to raise funds for treatment part 1 of 4
Go here to see the original:
Stem Cells Therapy MS1.mp4 - Video
09-02-2012 23:02 Stem Cell Therapy latest news - Jan 2012, MS options Contact Kevin for help to raise funds for treatment part 2 of 4
Read more from the original source:
Stem Cells Therapy MS2.mp4 - Video
09-02-2012 23:17 Stem Cell Therapy latest news - Jan 2012, MS options Contact Kevin for help to raise funds for treatment part 3 of 4
Read the original here:
Stem Cells Therapy MS3.mp4 - Video
08-02-2012 11:12 Stem Cell Treatment of Pro/Am dancer and orthodontist, Dr. Janet Vaughan. In attempt to get her dancing career back on track, Dr. Vaughan decided to undergo stem cell therapy at the Stem Cell Institute in Panama City, Panama. Dr. Jorge Paz, Medical Director at the Stem Cell Institute presents Dr. Vaughan's case discussing her injuries and subsequent recovery. After being unable to compete for 2 years, Dr. Vaughan is once again slated to compete on the professional dance circuit with her current professional partner, Mr. Eddie Stutts (Professional 10-Dance World Champion). From 2007-2009, Dr. Vaughan partnered with World Champion Tony Dovolani and competed extensively in the US, winning a National Reserve Pro/Am Rhythm title. Tony Dovolani is best known for his appearances on ABC's hit reality series, "Dancing with the Stars", and has teamed up with Chynna Phillips, Wendy Williams, Audrina Partridge, Kate Gosselin, Kathy Ireland, Susan Lucci, Jane Seymour and other celebrities on the show.
See the original post:
Stem Cell Therapy for Osteoarthritis and Sports Injuries: A Case Study - Video
01-02-2012 21:36 Notes from the interview: Nicholas Anderson - Author, NOC: British Secret Operations Big Pharma... must be careful in discussing reason for writing books is in part because of something along these lines medical doctor helped to exfiltrate from soviet union end of 1991 doctor wanted to meet... nicholas anderson flew to meet in moscow... bottom line: he claimed to have number of effective treatments and cures... MIND YOU... he's not trying to get your hopes up, but you should look into alternate treatments natural remedies. stem cell, energetic medicine is more detail in the book? when the book was written, it was non-fiction. but it didn't last to be a non-fiction novel. former secret operations must be cleared. large majority that was redacted or cleared from the fiction novel was about big pharma. certain things -are- in the book. also know that nicholas anderson was skeptical about these items first. even so, he wondered why aren't these alternative cures more widely known? the doctor appeared on a primetime show and the media prevented him from saying what he wanted to say... in a couple examples, they removed things he had said. they said the -opposite- of what he actually said. it was then that he realized he was on to something and he saw that happening. did this doctor have access to this medicine in the soviet union or was it secretive? in the beginning of communism, they did come up with things in medicine that the west never did come up with. this doctor had ...
Read the rest here:
Insights Into MI6: Big Pharma - Video
01-02-2012 13:37 Meet founders of Cord Blood Registry, Tom and Wendy. Hear why they started CBR -- a family business dedicated to helping people live healthier lives through cord blood stem cell medicine. Today, CBR has grown, but the attention to healthy families is the same. For more than 15 years, Cord Blood Registry has led the umbilical cord banking industry in technical innovations and provided families with peace of mind and hope. CBR's experience and dedication to quality has enabled CBR to help more clients use their cord blood stem cells in treatments than any other family bank. Our research and development efforts are focused on helping leading clinical researchers advance stem cell regenerative medicine that may help families in the future. Ultimate use of cord blood stem cells will be determined by the treating physician who will consider if they are applicable for the condition and should come from the patient or a suitable donor (like an HLA matched sibling). There is no guarantee that treatments being studied in the laboratory or in clinical trials will be available in the future. CBR is the preferred choice of OB/Gyns. © 2011 Cord Blood Registry. All rights reserved. Privacy Policy.
Here is the original post:
Meet the Founders of Cord Blood Registry - Video
12-01-2012 07:24 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.
Read the original post:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Leon B. Testimonial - Video
08-02-2012 09:53
See the rest here:
Healing Bones With Stem Cells - Video
03-02-2012 15:53 When Barry Goudy found out he had multiple sclerosis he feared the worst. Doctors told him he might lose his eye sight and the ability to walk. As a very active husband, father and hockey coach, Barry couldn't think of anything worse than losing his ability to get around. But then he learned of a new way to treat MS with a stem cell transplant. The transplant worked and today he's living proof of the miracles that can come from Adult Stem Cell Research.
Excerpt from:
Adult Stem Cell Sucess Stories - Barry Goudy - Video
A University of Minnesota-led research team has proposed a mechanism for the control of whether embryonic stem cells continue to proliferate and stay stem cells, or differentiate into adult cells like brain, liver or skin.
The work has implications in two areas. In cancer treatment, it is desirable to inhibit cell proliferation. But to grow adult stem cells for transplantation to victims of injury or disease, it would be desirable to sustain proliferation until a sufficient number of cells have been produced to make a usable organ or tissue.
The study gives researchers a handle on how those two competing processes might be controlled. It was performed at the university's Hormel Institute in Austin, Minn., using mouse stem cells. The researchers, led by Hormel Institute Executive Director Zigang Dong and Associate Director Ann M. Bode, have published a report in the journal Nature: Structure and Molecular Biology.
"This is breakthrough research and provides the molecular basis for development of regenerative medicine," said Dong. "This research will aid in the development of the next generation of drugs that make repairs and regeneration within the body possible following damage by such factors as cancer, aging, heart disease, diabetes, or paralysis caused by traumatic injury."
The mechanism centers on a protein called Klf4, which is found in embryonic stem cells and whose activities include keeping those cells dividing and proliferating rather than differentiating. That is, Klf4 maintains the character of the stem cells; this process is called self-renewal. The researchers discovered that two enzymes, called ERK1 and ERK2, inactivate Klf; this allows the cells to begin differentiating into adult cells.
The two enzymes are part of a "bucket brigade" of signals that starts when a chemical messenger arrives from outside the embryonic stem cells. Chemical messages are passed to inside the cells, resulting in, among other things, the two enzymes swinging into action.
The researchers also discovered how the enzymes control Klf4. They attach a small molecule--phosphate, consisting of phosphorus and oxygen--to Klf4. This "tag" marks it for destruction by the cellular machinery that recycles proteins.
Further, they found that suppressing the activity of the two enzymes allows the stem cells to maintain their self-renewal and resist differentiation. Taken together, their findings paint a picture of the ERK1 and ERK2 enzymes as major players in deciding the future of embryonic stem cells--and potentially cancer cells, whose rapid growth mirrors the behavior of the stem cells.
Klf4 is one of several factors used to reprogram certain adult skin cells to become a form of stem cells called iPS (induced pluripotent stem) cells, which behave similarly to embryonic stem cells.
Also, many studies have shown that Klf4 can either activate or repress the functioning of genes and, in certain contexts, act as either an oncogene (that promotes cancer) or a tumor suppressor. Given these and their own findings reported here, the Hormel Institute researchers suggest that the self-renewal program of cancer cells might resemble that of embryonic stem cells.
"Although the functions of Klf4 in cancer are controversial, several reports suggest Klf4 is involved in human cancer development," Bode said.
Established in 1942, the Hormel Institute is a world-renowned medical research center specializing in research leading to cancer prevention and control. It is a research unit of the University of Minnesota and a collaborative cancer research partner with Mayo Clinic.
See original here:
Hormel Institute study makes key finding in stem cell self-renewal
In Modern Pathology this week, researchers from the Seoul National University in South Korea report on the association between the patterns of promoter CpG island methylation of breast cancer subtypes and cancer stem cell phenotypes. The team analyzed methylation status of 15 promoter CpG island loci involved in breast cancer progression, and determined their cancer stem cell phenotypes. They found that "the number of CpG island loci methylated differed significantly between subtypes, and was highest in the luminal-HER2 subtype and lowest in the basal-like subtype. Methylation frequencies and levels in 12 of the 15 genes differed significantly between subtypes, and the basal-like subtype had significantly lower methylation frequencies and levels in nine of the genes than the other subtypes." These findings suggest that breast cancer subtypes have distinct methylation patterns and that these patterns are associated with different stem cell phenotypes, the authors add.
Also in Modern Pathology, a team of French researchers elucidates the role of the mTOR pathway in leiomyosarcomas and pleomorphic sarcomas. The team assessed PTEN level and protein expression as well as the activation of downstream pathways, in a large series of sarcomas. They observed PTEN partial genomic loss in 46 percent of the tumors and a loss of protein expression in up to 68 percent of the tumors. "PTEN mutations were rare, with only 4 point mutations in the 65 samples studied," the authors write. "Subsequent activation of AKT and mTOR pathways was only observed in 2 out of 3 of PTEN-deleted tumors. On the other hand, RICTOR, a major component of the mTOR complex 2, was significantly overexpressed in well-differentiated leiomyosarcomas." The results suggest a link between RICTOR over-expression and leiomyosarcomas oncogenesis, the researchers add.
Finally in Modern Pathology this week, Macher-Goeppinger et al. report on the molecular heterogeneity of TFE3 activation in renal cell carcinomas. The team examined TFE3 expression and underlying genetic alterations in a series of renal cell carcinomas with long-term follow-up information. They found that five out of a total 876 tumors had TFE3 translocations, but that 9 percent of all renal cell carcinoma samples showed some degree of TFE3 reactivity. "Interestingly, these cases were associated with high nuclear grade, greater tumor extent and metastatic disease as well as an unfavorable patient outcome on uni- and multivariate analysis," the authors write. "Fluorescence in situ hybridisation revealed TFE3 amplifications as an additional, novel mechanism leading to increased TFE3 expression levels."
Follow this link:
This Week in Modern Pathology
09-12-2011 00:46 Yash Sanghavi a visionary distributor in the pharmaceutical sector with his futuristic approach established Regenerative Medical Services in 2008. Regenerative Medical Services more popularly known as Regrow is one of the key players in stem cell therapy and cell banking in India. Sanghvi has done B. Com and MBA.
Original post:
IndiaMART Leaders of Tomorrow AWards 2011 - Regenerative Medical Services Pvt Ltd - Video
Creating custom organs for individual patients is an idea that's been bandied about for some time, but it's no longer just a possibility for the distant future. A woman has been fitted with a brand new jawbone built by a 3D printer. "The combination of additive manufacturing and tissue engineering can result in real organ printing," said medical engineer Jules Poukens. "In this case, bone is the organ."
They're building people out of 3D printers now -- parts, anyway. LayerWise announced Sunday that it has applied a process called "additive manufacturing" to produce a titanium total lower jaw implant for facial reconstruction. The project was developed in collaboration with partners from medical industries and academia.
This is the first complete patient-specific implant for the lower jaw. The complex implant design incorporates articulated joints and dedicated features. The implant restored a patient's facial aesthetics and allowed her to regain her speech within hours.
The printer uses a high-precision laser to selectively heat metal powder particles that fully melt to adhere to the next layer without using glue or binder liquid. The additive manufacturing prints functional implant shapes that could be very difficult to produce using standard metalworking processes.
The implant was awarded the 2012 additive manufacturing award by the Additive Manufacturing Network in Belgium due to the fact that additive manufacturing played the main role in the realization of this new technology.
Medical Field Breakthrough
This advancement in the field of implant reconstruction goes beyond facial surgery. The technology could change the way all implants are designed and produced.
"This is a real breakthrough, exhibiting the possibilities of additive manufacturing in the field of medicine," Peter Mercelis, PhD, managing director of LayerWise, told TechNewsWorld. "Not only patient-specific implants are possible, but the technology can also be applied for serial manufacturing of implants. Applications of additive manufacturing and 3D printing are not limited to facial surgery, but also orthopedic surgery and traumatology may benefit from this technology."
These methods will become more common as more people become aware of the benefits, suggested Mercelis.
"It is now very new, but when awareness grows, also the acceptance of this technology will follow," he said. "This kind of technology was originally developed as a prototyping technique, but we successfully used our additive manufacturing technology to make fully functional components instead of prototypes. "
Price Will Go Down
The medical industry will recognize the benefits of the patient-specific implant, Mercelis predicted, including reduced operation time, faster recovery, better long-term outcomes and better functionality for patients.
"Of course, a broad acceptance will also allow the technology to become cheaper," he said.
Body Parts Just for You
Implants using additive manufacturing allow new possibilities and are easier for the body to adapt to due to the detail that doctors are able to put into the individual pieces.
"We already use the technology on a large scale for patient-specific dental prostheses through our dental division, DentWise," said Mercelis. "Biocompatible implants may be designed with integrated porosities to allow the natural bone of the patient to really grow inside the implant to allow for an improved fixation of the implant. This offers many new possibilities; one can integrate drugs that promote bone formation."
In the future, combinations of titanium implants and biodegradable 3D printed structures may be used, Mercelis added.
The Future: Growing Our Own Bones
This revolutionary step in mandibular treatment was developed under the supervision of Jules Poukens, professor in medical engineering at University Hasselt Belgium and cranio-maxillofacial surgeon at Orbis Medical Center.
"The combination of additive manufacturing and tissue engineering can result in real organ printing," Poukens told TechNewsWorld. "In this case, bone is the organ."
Further research, involving the combination of 3D printing with human tissue, will be carried out in cooperation with the research institute Sirris. "3D printed resorbable scaffolds can be combined with stem cells from the patient in order to create a viable implant without the need to harvest large bone transplants from the patient," said Poukens.
Read the original:
3D Printer Joins Organ Replacement Revolution
02-02-2012 08:37 CCSVI Symposium 2011 - Second Annual Meeting Crowne Plaza Hotel Times Square, Manhattan New York, NY July 15-17, 2011 http://www.ccsvicare.com Stem Cell Therapy L. Grozdinski, MD Angiology Sector Chief Tokuda Hospital Sofia, Bulgaria [38 out of 46 videos]
Here is the original post:
L. Grozdinski, MD [Stem Cell Therapy | CCSVI Symposium 2011 - 38 of 46] - Video
The phase I trial follows promising studies on mice showing that such transplants were able to rebuild the structures of the inner ear, and some anecdotal evidence from humans, sparking hope of a cure for some forms of deafness.
One of those people is two-year-old Finn McGrath, who suffered brain damage after being deprived of oxygen during a prolonged and complicated delivery, according to his mother, Laura.
"His doctors told us he was at high risk for cerebral palsy, vision issues, hearing problems and mental retardation," she said in an interview with AFP.
Finn's early days were an all-out struggle to survive, so for his parents, learning that he had failed his hearing tests and had damaged hair cells -- the sensory receptors in the inner ear that pick up sounds -- was almost an afterthought.
He had organ failure, breathing problems, and his cerebral palsy left him unable to roll, crawl or walk, hold his head up, talk or eat.
As his parents searched for ways to help him, they came upon stories online that told of studies using cord blood to help children with cerebral palsy and other disorders.
Prior to his birth, the McGraths had arranged to privately bank his umbilical cord blood, a procedure that costs around $2,000 plus storage fees, and remains controversial among pediatricians.
Private companies such as the Cord Blood Registry, which is funding the Texas study on hearing loss, urge expecting parents to bank their umbilical cord blood and reserve it for personal use as a way to protect their family.
That advice runs counter to the guidelines issues by the American Academy of Pediatrics in 2007, which calls such claims "unsubstantiated" and says banking for personal or family use "should be discouraged" but is "encouraged" if it is to be stored in a bank for public use.
Since Finn's parents had already banked his, they enrolled him in cord blood trial for cerebral palsy in North Carolina and he received his first transplant in November 2009 when he was about seven weeks old.
A second transfusion followed and by May, his parents began to notice a change.
Nighttime noises, like an alarm on his food pump or the sound of ripping medical tape, would suddenly startle him awake, his mother recalled.
"He started vocalizing sounds and we could tell that he was anticipating things that we would say. Like, if he had heard a story a number of times or a song, he would smile like he recognized the song or the story."
Finn had a third infusion in September 2010, when he was one year old. Four months later, an otoacoustic emissions test (OAE), which plays a sound and picks up vibrations in the cochlea and hair cells, came back normal.
The early hearing tests that showed hearing loss were not exactly the same as the later tests that came back normal, so McGrath is cautious about comparing them directly, but she believes the cord blood transfusions may have helped.
"All I can tell you is anecdotally he was not able to hear for probably the first three or four months of his life, and then when he was about six to eight months old, he started hearing."
The hearing trial in Texas aims to take a first step in testing the safety, and later the efficacy, of transfusing cord blood in children age six weeks to 18 months who have sustained post-birth sensorineural hearing loss.
Some reasons that children lose their hearing at or after birth may include oxygen deprivation, head injury, infection, strong doses of antibiotics or loud noises.
Sensorineural hearing loss affects approximately six per 1,000 children, and there is no available medical treatment. Hearing aids or cochlear implants are typically offered to boost the ability of the damaged tissues.
"Stem cell therapy may potentially repair the damaged structures of the inner ear and restore normal hearing," lead investigator Sami Fakhri told AFP.
"We are at the initial stages of this process and the results are looking promising," Fakhri added.
Research using stem cells in cord blood, known as hematopoietic cells, is already under way on some types of brain injury, cerebral palsy, juvenile diabetes, kidney and lung disease, he said.
The new study at Memorial Hermann-Texas Medical Center is being funded by the Cord Blood Registry, a private bank, and those eligible must have already banked their own umbilical cord blood with CBR.
But to Stephen Epstein, an otolaryngologist in Maryland, that does not pose a conflict of interest, because separate medical institutions in Texas and Georgia are conducting the Food and Drug Administration-approved research.
"If both of them can reproduce the same results then I would say it has some validity to it," said Epstein, who is not involved in the study.
"This is certainly a welcome, acceptable experiment, but it should be looked at with caution and time will tell."
One patient is already enrolled and the study, which runs for one year, has room for nine more.
While Finn McGrath still faces many challenges due to his cerebral palsy, his mother is grateful for the things he can do.
"I don't know how much worse off he would have been without the stem cell transfusion," McGrath said, pointing to his normal cognition, lack of seizures, good hearing and vision.
"We remain hopeful that he will continue to improve."
(c) 2012 AFP
Read the rest here:
US begins stem cell trial for hearing loss
RED BANK, NJ--(Marketwire -02/07/12)- American CryoStem Corporation (OTCQB: CRYO.OB - News) announced today that it has completed providing stem cell processing services for Personal Cell Sciences Corp., a cutting edge manufacturer of anti-aging skin care products.
The study involves researching the regenerative function of a conditioned medium obtained from each participant's adipose (fat tissue) derived mesenchymal stem cells and their ability to promote the production or secretion of collagen, elastin and fibronectin related to skin wound healing.
John Arnone, CEO of American CryoStem and Founder of Personal Cell Sciences, commented, "CRYO's patented tissue culture media and its proprietary, aseptic adipose tissue processing methodology allows, as an added benefit for PCS customers to store a clinical grade sample of their own stem cells for future use in regenerative medicine. We are pleased to provide comprehensive Bio-Insurance storage solutions at our clinical facility."
The adipose tissue samples were acquired utilizing a mini-liposuction procedure. A total of sixty milliliters (approximately 2 fluid ounces) of adipose tissue was collected in the physician's office and sent to CRYO's laboratory for processing. Once processed, the resulting stromal vascular fraction (SVF) was forwarded to the Personal Cell Sciences laboratory for proprietary formulation for patient specific products.
"We are very excited to announce our service agreement and participation in this clinical study for Personal Cell Sciences. This contractual manufacturing agreement reinforces our capabilities to provide CRYO's exceptional clinical processing for relevant adult stem cell related products," said Anthony Dudzinski, COO of American CryoStem. "We look forward to our continued business relationship with PCS and expanding these services to other developers to speed their product's time to market."
About American CryoStem: American CryoStem Corporation (OTCQB: CRYO.OB - News) markets clinical processing products and services for Adipose (fat) Tissue and Adipose Derived Adult Stem Cells. CRYO's clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Original post:
American CryoStem Completes Cell Processing for Clinical Study
Source:
Source: